Insta
India's Drug Regulator Clears Phase-1 Human Clinical Trial Of Antisera With Potential To Treat Covid-19
ICMR Logo
In a major development in the fight against COVID-19, India's drug regulator has approved the human clinical trials of the highly purified antisera for treatment of Covid-19 which has been developed by Indian Council of Medical Research (ICMR) in collaboration with Hyderabad-based Biological E, reports Economic Times.
Developed by injecting an inactivated SARS-CoV-2 in horses, the potential Covid-19 treatment has received the permission of Drug Controller General of India (DCGI) to conduct Phase-1 human clinical trial.
The development was announced on Tuesday (6 October) by ICMR’s Director-General Dr Balram Bhargava.
During the study phase, a total of ten healthy horses were immunised with inactivated SARS-CoV-2 and after 21 days of immunisation, plasma samples were tested.
The results indicated the presence of SARS-CoV-2 targeting IgG antibodies. The pre-print version of the study has been posted on the Research Square platform.
Introducing ElectionsHQ + 50 Ground Reports Project
The 2024 elections might seem easy to guess, but there are some important questions that shouldn't be missed.
Do freebies still sway voters? Do people prioritise infrastructure when voting? How will Punjab vote?
The answers to these questions provide great insights into where we, as a country, are headed in the years to come.
Swarajya is starting a project with an aim to do 50 solid ground stories and a smart commentary service on WhatsApp, a one-of-a-kind. We'd love your support during this election season.
Click below to contribute.
Latest
